Volume 5.46 | Dec 9

Hematopoiesis News 5.46 December 9, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
BRAF Inhibitors Reverse the Unique Molecular Signature and Phenotype of Hairy Cell Leukemia and Exert Potent Anti-Leukemic Activity
Scientists investigated the biological and therapeutic importance of the activated BRAF-MEK-ERK pathway in hairy cell leukemia by exposing in vitro primary leukemic cells purified from 26 patients to clinically available BRAF (Vemurafenib; Dabrafenib) or MEK (Trametinib) inhibitors. [Blood] Abstract
mTeSR™1: Most Published Feeder-Free hPSC Maintenance Medium. Click to View Top Applications
PUBLICATIONS (Ranked by impact factor of the journal)
A Crucial Role for the Homeodomain Transcription Factor Hhex in Lymphopoiesis
Investigators found that loss of Hhex was tolerated in hematopoietic stem cells and myeloid lineages, but resulted in a progressive loss of B-lymphocytes in the circulation. [Blood] Abstract

The IKAROS Interaction with a Complex Including Chromatin Remodeling and Transcription Elongation Activities Is Required for Hematopoiesis
Scientists demonstrate that nucleosome remodeling and deacetylase and positive-transcription elongation factor b are assembled in a complex that can be recruited to specific genes by IKAROS. They show that an IKAROS mutant that is unable to bind protein phosphatase 1α cannot sustain gene expression and impedes normal differentiation of IkNULL hematopoietic progenitors. [PLoS Genet] Full Article

CD41 Marks the Initial Myelo-Erythroid Lineage Specification in Adult Mouse Hematopoiesis: Redefinition of Murine Common Myeloid Progenitor
Researchers show that the counterpart of GATA-1-activating myelo-erythroid progenitor resides also at the Lineage Sca-1+ c-Kit+ stage, expressing CD41 at a high level. [Stem Cells] Abstract

Anti-CD33 Chimeric Antigen Receptor Targeting of Acute Myeloid Leukemia
Scientists generated a second generation CD33-specific chimeric antigen receptor capable of redirecting cytolytic effector T cells against leukemic cells. Chimeric antigen receptor-modified T cells efficiently killed leukemia cell lines and primary tumor cells in vitro. [Haematologica] Abstract | Full Article

A Multicolor Panel of TALE-KRAB Based Transcriptional Repressor Vectors Enabling Knockdown of Multiple Gene Targets
Scientists show that the transcription activator-like effector (TALE)-Krüppel-associated box (KRAB) vector system when combined together with bone marrow transplantation could quickly knock down c-kit and PU.1 genes in hematopoietic stem and progenitor cells of recipient mice. [Sci Rep] Full Article

The Epigenetic Regulator CXXC Finger Protein 1 Is Essential for Murine Hematopoiesis
Mice homozygous for a conditional Cxxc1 deletion allele and carrying the inducible Mx1-Cre transgene were generated to assess CXXC finger protein 1 function in adult animals. [PLoS One] Full Article

Ultra-Endurance Exercise Induces Stress and Inflammation and Affects Circulating Hematopoietic Progenitor Cell Function
Scientists aimed to determine the impact of ultra-endurance exercise-induced stress on the number and function of circulating hematopoietic progenitor cells and hematological, inflammatory, clinical, metabolic, and stress parameters in moderately trained amateur athletes. [Scand J Med Sci Sports] Abstract


A Survey on Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia
Investigators analyzed the outcome of 229 adult patients with de novo acute leukemia, who received an unmanipulated haploidentical transplant as their first allogeneic hematopoietic stem cell transplantation. [Leukemia] Abstract

Superior Outcome Using Cyclosporin A Alone versus Cyclosporin A plus Methotrexate for Post-Transplant Immunosuppression in Children with Acute Leukemia Undergoing Sibling Hematopoietic Stem Cell Transplantation
The outcome of cyclosporin A (CSA) alone as graft-versus-host disease prophylaxis was compared to that of CSA combined with methotrexate in children with acute leukemia who underwent hematopoietic stem cell transplantation. [J Cancer Res Clin Oncol] Abstract

Multicenter Analysis of Treatment Outcomes in Adult Patients with Lymphoblastic Lymphoma Who Received Hyper-CVAD Induction followed by Hematopoietic Stem Cell Transplantation
Investigators evaluated the efficacy of hyper-CVAD induction and stem cell transplantation consolidation in LBL patients. The treatment responses of 49 patients treated with the hyper-CVAD regimen were retrospectively analyzed in 13 institutions. [Ann Hematol] Abstract

Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
Epigenetics in the Hematologic Malignancies
The authors provide an overview of the major protagonists in epigenetic regulation, their aberrant role in myeloid malignancies, prognostic significance and potential for therapeutic targeting. [Haematologica] Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
ARIAD Announces Longer-Term Safety and Efficacy Data of Ponatinib from PACE and Phase I Clinical Trials
ARIAD Pharmaceuticals, Inc. announced longer-term follow up from its Phase I and pivotal Phase II trials of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. [Press release from ARIAD Pharmaceuticals, Inc. discussing research presented at the 2014 American Society of Clinical Oncology (ASCO), Chicago] Press Release

Stem Cell Transplant without Radiation or Chemotherapy Pre-Treatment Shows Promise
Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant after pre-treatment with immunosuppressive drugs only. [Press release from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center discussing research presented at the 56th annual meeting of the American Society of Hematology, San Francisco] Press Release

Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood
Fate Therapeutics, Inc. released preclinical data highlighting the pharmacological properties of ex vivo programmed hematopoietic cells sourced from mobilized peripheral blood. [Press release from Fate Therapeutics, Inc. discussing research presented at the 56th annual meeting of the American Society of Hematology, San Francisco] Press Release

Kiadis Pharma Presents Positive Data from a Pre-Specified Interim Analysis of the Phase II Clinical Program with Its Lead Product ATIR™
Kiadis Pharma B.V. announced positive interim data from the ongoing Phase II clinical study with its lead product ATIR™. ATIR™ is a cell-based product designed to enable stem cell transplantations from partially matched family donors for blood cancer patients who do not have a standard of care stem cell donor available. [Press release from Kiadis Pharma B.V. discussing research presented at the 56th annual meeting of the American Society of Hematology, San Francisco] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
Pluristem Therapeutics Inc. announced that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem. The medical center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy will use preclinical models to assess the potential efficacy of PLX-RAD cells for treatment and prevention of hematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. [Pluristem Therapeutics Inc.] Press Release

MEI Pharma Completes Enrollment in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia
MEI Pharma, Inc. announced that it has completed enrollment in a Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia. [MEI Pharma, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW New and Emerging Trends In Oncology 2015 (NEO’15)
February 9-11, 2015
Hyderabad, India

NEW Stem Cells in Drug Discovery
June 2-3, 2015
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University)

NEW Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Research Positions – Pathways Governing Lineage Commitment from Hematopoietic Stem Cells (Karolinska Institute)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Position – Post-Transcriptional Control of Gene Expression in Hematopoietic Stem Cells (Lund University)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School At Houston)

Stem Cell Biology Program Director (Blood Research Institute of BloodCenter of Wisconsin)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us